Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cytomegalovirus vaccine (Triplex) - Helocyte

Next Previous
Drug Profile

Cytomegalovirus vaccine (Triplex) - Helocyte

Alternative Names: CMV-MVA triplex vaccine; Cytomegalovirus modified vaccinia Ankara triplex vaccine; Cytomegalovirus specific T-cells Triplex; Multi-CMV epitope modified vaccinia Ankara vaccine - Helocyte; MVA multi CMV epitopes; MVA-CMV-Triplex; Triplex

Latest Information Update: 20 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator City of Hope National Medical Center
  • Developer City of Hope National Medical Center; Helocyte
  • Class Cytomegalovirus vaccines; Gene therapies; Immunotherapies; Peptide vaccines; T lymphocyte cell therapies; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cytomegalovirus infections
  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 13 Aug 2024 Fortress Biotech completes enrolment in its phase-II trial for Cytomegalovirus infections (Prevention) in USA prior to August 2024 (IM), (NCT05099965)
  • 30 Apr 2024 City of Hope Medical Center initiates a phase II trial in Hematopoietic stem cell transplant (Prevention) in USA (IM) (NCT06059391)
  • 11 Apr 2024 National Institute of Allergy and Infectious Diseases plans a phase II COLT trial in Cytomegalovirus infections (Prevention) in USA (IM) in December 2024 (NCT06075745)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top